{"title":"(肺纤维化)。","authors":"J. Konno","doi":"10.32388/awmfgr","DOIUrl":null,"url":null,"abstract":"Bleomycin rodent models for basic research and pharmacological efficacy studies. Investigation of in-vivo efficacy of therapeutic candidates for preventive or therapeutic IPF treatment. Invasive but repetitive lung function measurements for monitoring of bleomycin-induced lung injury and fibrosis without destruction of the organism. Integration of histological examination as a qualitative method to assess IPF. PULMONARY FIBROSIS: IN-VIVO BLEOMYCIN MODELS FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE ITEM","PeriodicalId":17997,"journal":{"name":"Kekkaku : [Tuberculosis]","volume":"25 1","pages":"621-2"},"PeriodicalIF":0.0000,"publicationDate":"2020-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Pulmonary fibrosis].\",\"authors\":\"J. Konno\",\"doi\":\"10.32388/awmfgr\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Bleomycin rodent models for basic research and pharmacological efficacy studies. Investigation of in-vivo efficacy of therapeutic candidates for preventive or therapeutic IPF treatment. Invasive but repetitive lung function measurements for monitoring of bleomycin-induced lung injury and fibrosis without destruction of the organism. Integration of histological examination as a qualitative method to assess IPF. PULMONARY FIBROSIS: IN-VIVO BLEOMYCIN MODELS FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE ITEM\",\"PeriodicalId\":17997,\"journal\":{\"name\":\"Kekkaku : [Tuberculosis]\",\"volume\":\"25 1\",\"pages\":\"621-2\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2020-02-07\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Kekkaku : [Tuberculosis]\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.32388/awmfgr\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Kekkaku : [Tuberculosis]","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.32388/awmfgr","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Bleomycin rodent models for basic research and pharmacological efficacy studies. Investigation of in-vivo efficacy of therapeutic candidates for preventive or therapeutic IPF treatment. Invasive but repetitive lung function measurements for monitoring of bleomycin-induced lung injury and fibrosis without destruction of the organism. Integration of histological examination as a qualitative method to assess IPF. PULMONARY FIBROSIS: IN-VIVO BLEOMYCIN MODELS FRAUNHOFER INSTITUTE FOR TOXICOLOGY AND EXPERIMENTAL MEDICINE ITEM